CTI BioPharma Corp.
http://www.ctibiopharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From CTI BioPharma Corp.
Sun’s Leqvelsi Must Now Shine In Crowded JAK Inhibitor Field
The US FDA approved Leqvelsi for alopecia areata, making it the third drug in the class for the indication after Lilly’s Olumiant and Pfizer’s Litfulo.
McKinsey Exec On Where India Innovation Could Head, Leveraging Pharma’s GCC Ecosystem
McKinsey & Company’s senior partner and lead, life sciences practice (Asia), talks to Scrip about innovation niches that could interest Indian firms including the ADC space, using AI to increase confidence in research activities and how India could leverage big pharma’s expanding global capability centres (GCCs) to shape the wider R&D ecosystem.
Digital Health Roundup: Brain Talk On Seizures, Alzheimer's, Stress, Anxiety; Medtronic's OR Report; Health Care AI; UK Guidances
In this month’s Digital Health Roundup, Medtech Insight’s Marion Webb highlights AI discussions at the HLTH Europe conference and an interview with Motif Neurotech's CEO Jacob Robinson. Elizabeth Orr discusses DeepWell DTx's newly launched VR game for treating stress-related hypertension and anxiety. Natasha Barrow provides an overview of Digital Mental Health Technologies regulation in the UK and Brian Bossetta reports ‘the good and bad’ from Medtronic's report on digital technologies' use in the operating room.
Japan Phase III Wins, Asian Alliances Buoy Kissei's Linzagolix
While its European licensee is preparing for an imminent launch, Kissei has also been expanding its partnerships in Asia for female health product linzagolix. A new alliance is also being sought in the US to assist with a new trial and NDA refiling there.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Aequus BioPharma, Inc
- Cell Therapeutics, Inc.
- CTI Life Sciences Limited
- Systems Medicine, LLC
- CTI BioPharma Corporation
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice